The association between NQO1 Pro187Ser polymorphism and urinary system cancer susceptibility: A meta-analysis of 22 studies

Cancer Investigation

Volumn 33, Issue 2, 2015, Pages 39-40

  Zhang, Yan ^a   Yang, Dong ^a   Zhu, Jin Hong ^b   Chen, Min Bin ^a   Shen, Wen Xiang ^a   He, Jing ^c  

^a JIANGSU UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Cancer susceptibility; Meta analysis; NQO1; Polymorphism

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); NQO1 PROTEIN, HUMAN;

ARTICLE; ASIAN; BLADDER CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; KIDNEY CARCINOMA; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; URINARY TRACT CANCER; ASIAN CONTINENTAL ANCESTRY GROUP; BLADDER TUMOR; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; MALE; PATHOLOGY; PROSTATE TUMOR; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84921790278     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2014.998836     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374:239-249.
3. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234-241.
4. Golka K, Selinski S, Lehmann ML, Blaszkewicz M, Marchan R, Ickstadt K, Schwender H, Bolt HM, Hengstler JG. Genetic variants in urinary bladder cancer: Collective power of the "wimp SNPs". Arch Toxicol 2011;85:539-554.
5. Wu X, Hildebrandt MA, Chang DW. Genome-wide association studies of bladder cancer risk: A field synopsis of progress and potential applications. Cancer Metastasis Rev 2009;28:269-280.
6. Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 2010;501:116-123.
7. Siegel D, Yan C, Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 2012;83:1033-1040.
8. Guha N, Chang JS, Chokkalingam AP, Wiemels JL, Smith MT, Buffler PA. NQO1 polymorphisms and de novo childhood leukemia: A HuGE review and meta-analysis. Am J Epidemiol 2008;168:1221-1232.
9. Nioi P, Hayes JD. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydro-carbon receptor basic helix-loop-helix transcription factors. Mutat Res 2004;555:149-171.
10. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:979-987.
11. Choi JY, Lee KM, Cho SH, Kim SW, Choi HY, Lee SY, Im HJ, Yoon KJ, Choi H, Choi I, et al. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 2003;13:349-355.
12. Wang YH, Lee YH, Tseng PT, Shen CH, Chiou HY. Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan. J Cancer Res Clin Oncol 2008;134:203-209.
13. Pandith AA, Khan NP, Shah ZA, Shah AM, Wani SM, Siddiqi MA. Association of bladder cancer risk with an NAD(P)H:quinone oxidoreductase polymorphism in an ethnic Kashmiri population. Biochem Genet 2011;49:417-426.
14. Fu J, Chen B. Relationship between genetic polymorphisms of CYP1A1, NQO1 and EPHX1 and susceptibility to bladder cancer. Chin J Cancer Prev Treat 2013;20:10-14.
15. Huang ZM, Chen HA, Chiang YT, Shen CH, Tung MC, Juang GD. Association of polymorphisms in iNOS and NQO1 with bladder cancer risk in cigarette smokers. J Chin Med Assoc 2014;77:83-88.
16. Mandal RK, Dubey S, Panda AK, Mittal RD. Genetic variants of NQO1 gene increase bladder cancer risk in Indian population and meta-analysis. Tumour Biol 2014; 35:6415-6423.
17. Hamajima N, Matsuo K, Iwata H, Shinoda M, Yamamura Y, Kato T, Hatooka S, Mitsudomi T, Suyama M, Kagami Y, et al. NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 2002;7:103-8.
18. Mandal RK, Nissar K, Mittal RD. Genetic variants inmetabolizing genesNQO1,NQO2,MTHFR and risk of prostate cancer: A study from North India. Mol Biol Rep 2012;39:11145-11152.
19. Park SJ, Zhao H, Spitz MR, Grossman HB, Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res 2003;536:131-137.
20. Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, Carta A, Hautefeuille A, Porru S. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis 2004;25:973-978.
21. Terry PD, Umbach DM, Taylor JA. No association between SOD2 or NQO1 genotypes and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 2005;14:753-754.
22. Figueroa JD, Malats N, Garcia-Closas M, Real FX, Silverman D, Kogevinas M, Chanock S, Welch R, Dosemeci M, Lan Q et al. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 2008;29:1955-1962.
23. Stoehr CG, Nolte E, Wach S, Wieland WF, Hofstaedter F, Hartmann A, Stoehr R. NAD(P)H:quinone oxidoreductase 1 (NQO1) P187S Polymorphism and Prostate Cancer Risk in Caucasians. Int J Mol Sci 2012;13:10959-10969.
24. Longuemaux S, Delomenie C, Gallou C, Mejean A, Vincent-Viry M, Bouvier R, Droz D, Krishnamoorthy R, Galteau MM, Junien C, et al. Candidate geneticmodifiers of individual susceptibility to renal cell carcinoma: A study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res 1999;59:2903-2908.
25. Goerlitz D, Amr S, Dash C, Saleh DA, El Daly M, Abdel-Hamid M, El Kafrawy S, Hifnawy T, Ezzat S, Abdel-Aziz MA, et al. Genetic polymorphisms in NQO1 and SOD2: Interactions with smoking, schistosoma infection, and bladder cancer risk in Egypt. Urol Oncol 2014;32:47 e15-20.
26. Schulz WA, Krummeck A, Rosinger I, Eickelmann P, Neuhaus C, Ebert T, Schmitz-Drager BJ, Sies H. Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 1997;7:235-239.
27. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, Wijkstrom H, Larsson P, Kumar R, Hemminki K. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 2004;25:729-734.
28. Moore LE, Wiencke JK, Bates MN, Zheng S, Rey OA, Smith AH. Investigation of genetic polymorphisms and smoking in a bladder cancer case-control study in Argentina. Cancer Lett 2004;211:199-207.
29. Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis 2005;26:1263-1271.
30. Steiner M, Hillenbrand M, Borkowsi M, Seiter H, Schuff-Werner P. 609 C -> T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia. Cancer Lett 1999;135:67-71.
31. Steinbrecher A, Rohrmann S, Timofeeva M, Risch A, Jansen E, Linseisen J. Dietary glucosinolate intake, polymorphisms in selected biotransformation enzymes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2010;19:135-143.
32. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
34. He J, Liao XY, Zhu JH, Xue WQ, Shen GP, Huang SY, Chen W, Jia WH. Association of MTHFR C677T and A1298C polymorphisms with non-Hodgkin lymphoma susceptibility: Evidence from a meta-analysis. Sci Rep 2014;4:6159.
35. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
36. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
37. Zhong R, Liu L, Zou L, Sheng W, Zhu B, Xiang H, Chen W, Chen J, Rui R, Zheng X, et al. Genetic variations in the TGFbeta signaling pathway, smoking and risk of colorectal cancer in a Chinese population. Carcinogenesis 2013;34:936-942.
38. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:969-978.
39. Heck JE, Moore LE, Lee YC, McKay JD, Hung RJ, Karami S, Gaborieau V, Szeszenia-Dabrowska N, Zaridze DG, Mukeriya A, et al. Xenobiotic metabolizing gene variants and renal cell cancer: A multicenter study. Front Oncol 2012;2:16.
40. Toncheva D, Dimitrov T, Stojanova S. Etiology of Balkan endemic nephropathy: A multifactorial disease? Eur J Epidemiol 1998;14:389-394.
41. Basu S, Brown JE, Flannigan GM, Gill JH, Loadman PM, Martin SW, Naylor B, Puri R, Scally AJ, Seargent JM, et al. NAD(P)H:quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: Relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C. Int J Oncol 2004;25:921-927.
42. Sanyal S, Ryk C, De Verdier PJ, Steineck G, Larsson P, Onelov E, Hemminki K, Kumar R. Polymorphisms in NQO1 and the clinical course of urinary bladder neoplasms. Scand J Urol Nephrol 2007;41:182-190.
43. Ryk C, Kumar R, Sanyal S, de Verdier PJ, Hemminki K, Larsson P, Steineck G, Hou SM. Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett 2006;241:142-149.
44. Fu J, Chen B. Relationship between genetic polymorphism of NQO1 and susceptibility to bladder cancer. Journal of Chinese Oncology 2012;18:561-564.
45. Amr S, Dawson R, Saleh DA, Magder LS, George DM, El-Daly M, Squibb K, Mikhail NN, Abdel-Hamid M, Khaled H, et al. Pesticide, gene polymorphisms and bladder cancer among Egyptian agricultural workers. Arch Environ Occup Health 2014;70: 19-26.
46. Ergen HA, Gormus U, Narter F, Zeybek U, Bulgurcuoglu S, Isbir T. Investigation of NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in prostate cancer. Anticancer Res 2007;27:4107-4110.
47. Basma HA, Kobeissi LH, Jabbour ME, Moussa MA, Dhaini HR. CYP2E1 and NQO1 genotypes and bladder cancer risk in a Lebanese population. Int J Mol Epidemiol Genet 2013;4:207-217.
48. Guo ZJ, Feng CL. The NQO1 rs1800566 polymorphism and risk of bladder cancer: Evidence from 6,169 subjects. Asian Pac J Cancer Prev 2012;13:6343-6348.
49. Gong M, Yi Q, Wang W. Association betweenNQO1 C609T polymorphism and bladder cancer susceptibility: A systemic review and meta-analysis. Tumour Biol 2013;34:2551-2556.
50. Zhang H, Wen X, Lu X. Association between NAD(P)H:quinone oxidoreductase 1 rs1800566 polymorphism and risk of bladder cancer. Tumour Biol 2013;34:3377-3381.